Sygnis sells its own-brand TruePrime kits through its website and an international distributor network. A new enzyme, SunScript, has been added to the range. Kits may also be sold as OEM products with next-generation sequencing systems. A new kit for research in cancer diagnosis and monitoring could be added in 2016. Cash at 31 March was €2.5m. Q115 had revenues of €76k; total cash outflow was €1.29m.
